Merck & Company Inc (MRK) is next scheduled to report earnings on Aug 4, 2026 (before market open). The consensus analyst EPS estimate for the upcoming quarter is $2.15.
Heading into this report, the model's fair value estimate sits 15.1% below the current price (model fair value differential below current price). Descriptive context only — not a forecast of the earnings result.
Equity Rank computed model fair value for MRK from 9 independent valuation methods with sufficient data. 2 place fair value above the current price of $127.86, and 7 place it below. The model-blended estimate lands at $108.50 — a model fair value differential of 15.1% below the current price under these model assumptions. The larger group places fair value below the current price.
Equity Rank's fundamental strength composite scores MRK at 70.6/100 (B+, Strong), blending profitability, balance-sheet, and cash-flow quality. Over the trailing three years, free cash flow has compounded at -5.6% per year and gross margin has moved +1.3 pp. Its SAVE composite score has moved -0.1 over the past 30 days.
Merck & Company Inc (MRK) is analyzed on Equity Rank using the S·A·V·E framework: Sentiment, Analyst consensus, Valuation (DCF, Graham, multiples), and Earnings quality. The consensus fair value is a blend of multiple models designed to surface potential mispricings versus current market price.
Equity Rank provides institutional-depth valuation research on 3,000+ US equities. Data is refreshed daily and combines quantitative models with AI-driven qualitative analysis.
Intrinsic Value Calculator · DCF Calculator · Margin of Safety Calculator